Form 8-K - Current report:
SEC Accession No. 0001178913-25-000102
Filing Date
2025-01-14
Accepted
2025-01-14 06:01:48
Documents
17
Period of Report
2025-01-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2432542.htm   iXBRL 8-K 51351
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 1277344
3 EXHIBIT 99.2 exhibit_99-2.htm EX-99.2 1191669
8 slxn_img01.jpg GRAPHIC 38245
  Complete submission text file 0001178913-25-000102.txt   2910708

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250114.xsd EX-101.SCH 4741
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250114_def.xml EX-101.DEF 18264
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250114_lab.xml EX-101.LAB 27749
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250114_pre.xml EX-101.PRE 20506
20 EXTRACTED XBRL INSTANCE DOCUMENT zk2432542_htm.xml XML 6551
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 25527591
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)